Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsJr vyas

    Jr Vyas

    Jump to

    • Dishman Pharma rises 20% on USFDA approval for cancer drug

      The company has received United States Food and Drug Administration (USFDA) approval for cancer drug Zejula Capsules, for Tesaro Inc.

    • Not received warning from USFDA on Clovis: Dishman Pharma

      JR Vyas, CMD, Dishman Pharma in an interview to CNBC-TV18 clarified that the company had not received any warning from US FDA on Clovis issue.

    • Dishman Pharma confident of meeting revenue guidance: CMD

      The company is on track to meet their revenue guidance for the year, said JR Vyas, CMD of Dishman Pharma.

    • Dishman Pharma slips 7% on income tax survey woes

      JR Vyas, chairman and MD said that tax men quizzed the company over tax exemption for a sale of land from Dishman SEZ to Dishman Pharma for Rs 42 crore. The exemption under (section) 80 existed then, but now the I-T is demanding tax for the same, Vyas tells CNBC-TV18.

    • Contract research to boost performance in FY13: Dishman

      In an interview with CNBC-TV18, JR Vyas, MD of Dishman Pharma said the the contract research income is going to boost the company's performance through FY13.

    • Dishman Pharma to repay Rs 100cr debt in FY13

      Pharma player Dishman Pharma is looking to cut its debt of Rs 100 crore in FY13. JR Vyas, managing director, Dishman Pharma told CNBC-TV18 that the company would be selling its SEZ land to repay debt.

    • Dishman Pharma expects 25% growth in FY13

      Dishman Pharmaceuticals posted a 13.24% topline growth in the fourth quarter of FY12 and reported a consolidated net profit of Rs 312.94 million for the quarter ended 31 March, 2012, up 37.30% from Rs 227.92 million in the corresponding quarter last year.

    • FY12 profit to be better than FY11: Dishman Pharma

      Dishman's Managing Director JR Vyas expects its key clients Abbott's contribution to grow by 50%. He further expects some more product orders coming in from Abbott in FY13.

    • Dishman Pharma eyes over 15% topline growth going forward

      Managing director of Dishman Pharmaceuticals, JR Vyas expects the topline growth to be 15% or even more going forward. He also added that the bottomline will grow in the second half too.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347